Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

被引：87
|
作者：
Jacobson, Caron
Chavez, Julio C.
Sehgal, Alison R.
William, Basem M.
Munoz, Javier
Salles, Gilles
Munshi, Pashna N.
Casulo, Carla
Maloney, David
De Vos, Sven
Reshef, Ran
Leslie, Lori A.
Yakoub-Agha, Ibrahim
Oluwole, Olalekan O.
Fung, Henry C. H.
Rosenblatt, Joseph D.
Rossi, John M.
Goyal, Lovely
Plaks, Vicki
Yang, Yin
Lee, Jennifer
Godfrey, Wayne
Vezan, Remus
Avanzi, Mauro P.
Neelapu, Sattva S.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-136834
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Earlier Steroid Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 12 - 14
  • [42] COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) AND TISAGENLECLEUCEL (TISA-CEL) IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL) IN CANADA
    Ball, G.
    Kuruvilla, J.
    Boodoo, C.
    Jain, M. D.
    VALUE IN HEALTH, 2021, 24 : S39 - S39
  • [43] THE ECONOMIC AND HUMANISTIC BURDEN OF RELAPSED/REFRACTORY (R/R) INDOLENT NON-INDOLENT NON-HODGKIN'S LYMPHOMA (INHL): AN EVIDENCE GAP ANALYSIS
    Leinwand, B.
    Brown, J.
    Rai, K.
    Inocencio, T. J.
    Agatep, B.
    VALUE IN HEALTH, 2014, 17 (03) : A236 - A236
  • [44] Primary overall survival (OS) analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy in relapsed/refractory large B-cell lymphoma (R/R LBCL)
    Dreger, P.
    Westin, J.
    Oluwole, O.
    Kersten, M. J.
    Miklos, D.
    Perales, M. -A
    Ghobadi, A.
    Rapoport, A.
    Sureda, A.
    Jacobson, C.
    Farooq, U.
    van Meerten, T.
    Ulrickson, M.
    Elsawy, M.
    Leslie, L.
    Chaganti, S.
    Dickinson, M.
    Yang, Y.
    Schupp, M.
    To, C.
    Locke, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 271 - 272
  • [45] Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.
    Locke, Frederick Lundry
    Bartlett, Nancy L.
    Jacobson, Caron A.
    Oluwole, Olalekan O.
    Munoz, Javier
    Lekakis, Lazaros J.
    Topp, Max S.
    Avivi, Irit
    Kim, Jenny J.
    Chu, Rong
    Zheng, Lianqing
    Rossi, John M.
    Bot, Adrian
    Neelapu, Sattva Swarup
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [46] CLINICAL AND BIOLOGIC COVARIATES OF OUTCOMES IN ZUMA-1: A PIVOTAL TRIAL OF AXICABTAGENE CILOLEUCEL (AXI-CEL; KTE-C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON-HODGKIN LYMPHOMA (NHL)
    Locke, F. L.
    Neelapu, S. S.
    Bartlett, N. L.
    Lekakis, L. J.
    Miklos, D.
    Jacobson, C. A.
    Braunschweig, I.
    Oluwole, O.
    Siddiqi, T.
    Lin, Y.
    Timmerman, J.
    Reagan, P. M.
    Bot, A.
    Rossi, J.
    Navale, L.
    Jiang, Y.
    Aycock, J.
    Elias, M.
    Wiezorek, J.
    Go, W. Y.
    HAEMATOLOGICA, 2017, 102 : 172 - 172
  • [47] Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin Lymphoma: Real-World Data in Chinese Population
    Yan, Zixun
    Zou, Dehui
    Li, Yuhua
    Zhu, Xiaojian
    Ji, Dongmei
    Qian, Wenbin
    Lu, Ying
    Ji, Chunyan
    Zhou, Keshu
    Jing, Hongmei
    Yang, Hua
    Li, Lanfang
    Li, Fei
    Xu, Kailin
    Niu, Ting
    Wu, Depei
    Hu, Yu
    Zhao, Weili
    BLOOD, 2023, 142
  • [48] Health Utilities for Patients with Relapsed or Refractory Large B-Cell Lymphoma (R/R-LBCL): Ad Hoc Analysis From an Axicabtagene Ciloleucel (Axi-cel) Safety Management Study
    Lin, Vincent W.
    Jiang, Yizhou
    Chuang, Ling Hsiang
    Navale, Lynn
    Cheng, Paul
    Purdum, Anna
    BONE MARROW TRANSPLANTATION, 2018, 53 : 879 - 879
  • [49] Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma
    Locke, Frederick L.
    Miklos, David B.
    Jacobson, Caron
    Perales, Miguel-Angel
    Kersten, Marie Jose
    Oluwole, Olalekan O.
    Ghobadi, Armin
    Rapoport, Aaron P.
    McGuirk, Joseph P.
    Pagel, John M.
    Munoz, Javier
    Farooq, Umar
    Van Meerten, Tom
    Reagan, Patrick M.
    Sureda, Anna
    Flinn, Ian W.
    Vandenberghe, Peter
    Song, Kevin
    Dickinson, Michael
    Minnema, Monique C.
    Riedell, Peter A.
    Leslie, Lori A.
    Chaganti, Sridhar
    Yang, Yin
    Filosto, Simone
    Schupp, Marco
    To, Christina
    Cheng, Paul
    Gordon, Leo I.
    Westin, Jason R.
    BLOOD, 2021, 138
  • [50] The Phase 3, Randomized Study of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma: ZUMA-7
    Schmitz, N.
    Oluwole, O. O.
    Bishop, M. R.
    Gisselbrecht, C.
    Gordon, L. I.
    Kersten, M. J.
    Maloney, D. G.
    Caballero, M. D.
    Kuruvilla, J.
    Song, K. W.
    Jacobson, C. A.
    Nastoupil, L. J.
    Riedell, P.
    Jiang, Y.
    Rossi, J. M.
    Lee, L.
    Cheng, P.
    Locke, F. L.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 90 - 91
12345